K. Nackaerts (Leuven, Belgium), R. G. Wiewrodt (Muenster, Germany)
The second therapeutic intervention in malignant effusion trial (TIME2): A randomised controlled trial to assess the efficacy and safety of patient controlled malignant pleural effusion drainage by indwelling pleural catheter compared to chest drain and talc slurry pleurodesis E. Mishra, H. Davies, J. Wrightson, A. Stanton, A. Guhan, C. Davies, J. Grayez, R. Harrison, A. Prasad, N. Crosthwaite, Y. C. G. Lee, R. Miller, B. Kahan, N. Rahman (Cardiff, Swindon, South Tees, Reading, Banbury, North Tees, High Wycombe, London, United Kingdom; Perth, Australia)
| |
Impact of indwelling pleural catheter on quality of life in management of malignant pleural effusion in patients with advanced malignancies M.J. Lorenzo, M. Modesto, M. Muñoz, J. Perez, A. Santa-Cruz, E. Bollo, S. Fernández, R. Cordovilla, M. Lanchas, J.A. Perez-Fidalgo, E. Cases (Valencia, Castellón, Murcia, Spain)
| |
Mesothelioma in Sunderland U.K 1998 -2011: Chemotherapy usage and impact on survival J. Anderson, S. Pollock, G. Probert, S. Murphy, I. Taylor, K. Sridharan, H. Clague (Sunderland, United Kingdom)
| |
Efficacy and safety of autologous blood pleurodesis versus talc pleurodesis in patients with malignant pleural effusions: Preliminary results G. Sari, H. Yildirim, G. Ak, M. Metintas (Eskisehir, Turkey)
| |
Time to diagnosis and time to therapy in patients with malignant pleural mesothelioma (MPM) compared to patients with lung cancer in Denmark 2007 to 2011. A quality assurance analysis N.C.G. Hansen, C.B. Laursen, K.E. Olsen, P. Licht (Odense, Denmark)
| |
Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma C. Tabata, A. Murakami, R. Tabata, H. Okuwa, T. Nakano (Nishimomiya, Amagasaki, Japan)
| |
Inhibition of osteopontin modulates tumor-stimulated immune response and suppresses mesothelioma progression I. Psallidas, S. Magkouta, A. Pappas, C. Moschos, M.E. Vazakidou, C. Roussos, G. Stathopoulos, I. Kalomenidis (Athens, Greece)
| |